No Data
No Data
Leadman (300289.SZ): Net loss of 2.751 million yuan in the first quarter
Gelonghui, April 25 | Leadman (300289.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 94.6241 million yuan, down 12.51% year on year; net profit attributable to shareholders of listed companies - 27.51 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 4.8794 million yuan; basic earnings per share - 0.0050 yuan.
Leadman (300289.SZ): Currently, e-commerce platforms and cross-border e-commerce platform promotion channels are not involved
Gelonghui, April 8 | Leadman (300289.SZ) said on the investor interactive platform that at this stage, the company promotes products and brands through various forms such as online marketing, public account tweets, academic marketing, thematic salons, expert satellite meetings, product promotion conferences, etc., and is actively building celebrity classrooms and scientific research courses as academic leading platforms to increase the recognition and satisfaction of end users with the company's products through academic brand influence, so as to strengthen academic construction of benchmark hospitals and in-depth cooperation with KOL experts. Currently, e-commerce platforms are not involved. Promotion channels with cross-border e-commerce platforms
Leadman (300289.SZ): Net profit of 15.337 million yuan in 2023, plan to distribute 0.1 yuan to 10 shares
On March 27, GLONGHUI | Leadman (300289.SZ) released its 2023 annual report. Operating income was 460 million yuan, down 34.62% year on year, and net profit was 15.337 million yuan, reversal of year-on-year losses. After deducting non-net profit of 8.79 million yuan, reversing losses year-on-year, with basic earnings of 0.03 yuan per share. A cash dividend of 0.1 yuan is distributed to all shareholders for every 10 shares.
Leadman (300289.SZ): The R&D and production base has a production capacity of 250,000 liters of in vitro biochemical diagnostic reagents and 2,500 liters of in vitro immunodiagnostic reagents
Gelonghui, March 21丨Leadman (300289.SZ) said on the investor interactive platform that the company's R&D and production base has adopted high industry standards and has built a large-scale, advanced and efficient fully automated diagnostic reagent production line. The assembly line includes four parallel production lines, which fully automate the preparation, canning, labeling and packaging, and has a production capacity of 250,000 liters of in vitro biochemical diagnostic reagents and 2,500 liters of in vitro immune diagnostic reagents. After being awarded the “2018 Beijing Intelligent Manufacturing Benchmark Enterprise”, the company passed the “2022 Beijing Intelligent Manufacturing Benchmark Enterprise (Figure)
Leadman (300289.SZ): Joint Medical, a shareholder, has launched a fully automated fluorescent staining intelligent analysis system (Gis3000 series), which can provide intelligent morphological panoramic solutions for gynecological inflammation
Glonghui, March 21丨Leadman (300289.SZ) said on the investor interactive platform that United Medicine, in which the company invests, has launched a fully automated fluorescence staining intelligent analysis system (Gis3000 series), which can provide an intelligent morphological panoramic solution for gynecological inflammation. Full process automation combined with artificial intelligence AI technology can automatically smear, automatically dye, automatically dry, automatically focus, automatically scan, label, screen and output report functions for clinical use.
Leadman (300289.SZ): The current business focuses on the in vitro diagnosis industry and does not involve drugs
Gelonghui, March 15 | An investor asked Leadman (300289.SZ) on the investor interactive platform, “Please ask if your company has drugs with independent intellectual property rights developed through technical means such as chemical synthesis, genetic engineering, and antibody engineering.” The company replied that the company's current business focuses on the in vitro diagnosis industry and does not involve drugs.
No Data